Evidence map›Paper›PMID 36996375›Full record

ArticleJCO precision oncology2023

PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study.

Mifen Chen, Zhenghang Wang, Zimin Liu, Ting Deng, Xiaodong Wang, Zhiwei Chang, Qi Zhang, Wenlei Yang, Ning Liu, Zhi Ji and 46 more

Open access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

56 authors at 20 institutions in 1 country.

Mifen ChenDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.ORCID 0000-0002-2400-4837
Zhenghang WangDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Zimin LiuDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Ting DengDepartment of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Xiaodong WangDepartment of Oncology, Peking University Shougang Hospital, Beijing, China.
Zhiwei ChangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Qi ZhangDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Wenlei YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Laboratory of Genetics, Peking University Cancer Hospital & Institute, Beijing, China.ORCID 0000-0001-9065-649X
Ning LiuDepartment of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
Zhi JiDepartment of Gastrointestinal Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Xiaotian ZhangDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Xicheng WangDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Zhi PengDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Yi LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yujuan CaoDepartment of Oncology, Peking University Shougang Hospital, Beijing, China.
Xuan JinDepartment of Medical Oncology, Peking University First Hospital, Beijing, China.
Hongxia LuDepartment of Gastroenterology, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, Shanxi, China.
Huajun QuDepartment of Medical Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.
Yong TangDepartment of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Chunlei XuDepartment of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.
Weijia FangDepartment of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Hangyu ZhangDepartment of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
Dong YanDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China.
Li WangDepartment of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China.
Jiayi LiDepartment of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.
Jingdong ZhangDepartment of Medical Oncology, People's Hospital of Inner Mongolia Autonomous Region, Hohhot, Inner Mongolia, China.
Qiwei WangDepartment of Medical Oncology, People's Hospital of Inner Mongolia Autonomous Region, Hohhot, Inner Mongolia, China.
Liying XueDepartment of Gastroenterology and Hepatology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Fei YinDepartment of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.
Guangjie HanDepartment of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China.ORCID 0000-0003-2256-9356
Zhiqiang ChengDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Qing LiuDepartment of Medical Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Yongdong JinDepartment of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Yinjie ZhangDepartment of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Lanxing LiDepartment of Medical Oncology and Radiation Sickness, Peking University Third Hospital, Beijing, China.
Baoshan CaoDepartment of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Yanhong YaoDepartment of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhiyu ChenDepartment of Abdominal Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Jianling ZouDepartment of Abdominal Medical Oncology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China.
Jieer YingDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Qing WeiDepartment of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, China.
Tiantian TianDepartment of Oncology, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou, Henan, China.
Weifeng ZhaoDepartment of Oncology, Guangdong Provincial Hospital of Chinese Medicine, The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Longmei LiDepartment of Oncology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China.
Tong ZhangDepartment of Oncology, Dalian University Affiliated Xinhua Hospital, Dalian, Liaoning, China.ORCID 0000-0002-4041-0499
Fanghua SongDepartment of Internal Medicine, Baotou Cancer Hospital, Baotou, Inner Mongolia, China.
Ya-Er BaCancer Center, Suining Central Hospital, Suining, Sichuan, China.
Na LiDepartment of Oncology Rehabilitation, Zhengzhou Central Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan, China.
Hui GaoDepartment of Oncology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Yinghua JiDepartment of Medical Oncology, Manzhouli People's Hospital, Manzhouli, Inner Mongolia, China.
Liying BaoMedical Affairs, 3D Medicines, Inc, Shanghai, China.
Xiaochen ZhaoMedical Affairs, 3D Medicines, Inc, Shanghai, China.
Jinping CaiMedical Affairs, 3D Medicines, Inc, Shanghai, China.
Zheping YuanMedical Affairs, 3D Medicines, Inc, Shanghai, China.
Lin ShenDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.ORCID 0000-0002-8798-4756
Jian LiDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing, China.
Peking University · CNUniversity of Electronic Science and Technology of China · CNHua Medicine (China) · CNZhejiang Cancer Hospital · CNHebei Medical University · CNQingdao University · CNBeijing Luhe Hospital Affiliated to Capital Medical University · CNFirst Affiliated Hospital of Xinxiang Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNFudan University Shanghai Cancer Center · CNGuangzhou University of Chinese Medicine · CNInner Mongolia People's Hospital · CNTianjin Medical University Cancer Institute and Hospital · CNXiamen University · CNXinjiang Medical University · CNZhejiang University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDalian University · CNHenan University · CNPeking University Shougang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo investigate the efficacy of PD-1/PD-L1 inhibitors plus chemotherapy versus anti-PD-1/PD-L1 monotherapy in advanced microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers.

methodsWe retrospectively recruited patients with MSI/dMMR gastrointestinal cancer who received anti-PD-1/PD-L1 with or without chemotherapy and compared objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) of PD-1/PD-L1 inhibitor plus chemotherapy (chemo-anti-PD-1/PD-L1 group) and PD-1/PD-L1 inhibitor alone (anti-PD-1/PD-L1 group). Propensity score-based overlap weighting analysis was conducted to adjust the baseline covariable imbalance. Sensitivity analysis was performed to confirm the stability of the results by propensity score matching and multivariable Cox and logistic regression models.

resultsA total of 256 patients were eligible, with 68 and 188 receiving chemo-anti-PD-1/PD-L1 and anti-PD-1/PD-L1, respectively. The chemo-anti-PD-1/PD-L1 group showed significant improvements versus the anti-PD-1/PD-L1 group in ORR (61.8%

conclusionChemo-anti-PD-1/PD-L1 is superior to anti-PD-1/PD-L1 in MSI/dMMR gastrointestinal cancers with improved efficacy.

Indexed as

Colorectal NeoplasmsImmune Checkpoint InhibitorsB7-H1 AntigenBrain NeoplasmsHumansMicrosatellite InstabilityNeoplastic Syndromes, HereditaryRetrospective StudiesB7-H1 AntigenImmune Checkpoint Inhibitors

Identifiers

PMID36996375
PMCPMC10309553
OpenAlexW4361266024

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.